Treatment of Insomnia and Glucose Metabolism

• Status: Completed
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Available data suggest that obtaining adequate sleep is associated with a better ability of the body to use carbohydrates as a source of energy and a lower risk of developing diabetes. The sleeping pill, Eszopiclone (Lunesta), has been approved by the Food and Drug Administration for the treatment of people who complain of trouble falling or staying asleep. This study will examine the hypothesis that the use of Eszopiclone (Lunesta) to improve the sleep of people with insomnia may also improve the use of sugar in their body.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Chicago
• Treatments: Eszopiclone; Insulin; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• age between 35 and 64

• must have long-standing trouble falling or staying asleep

• BMI between 22 and 34 kg/m2

Exclusion Criteria:

• sleep apnea or other sleep disorder other than insomnia

• diagnosis of diabetes requiring treatment with pills or insulin

• smoking

• night or shift work

• presence of a medical condition that can disrupt sleep

• women only: irregular menstrual periods or pregnancy

• use of medications/compounds that can disrupt sleep